Physician profile
Jane N Winter
NPI 1306864160
$32,964.99
in general payments reported to CMS, 2019-2025
7 companies · $5,507 in 2025
The $5,507 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,845 · 2020: $1,250 · 2021: $5,000 · 2022: $27.17 · 2023: $11K · 2024: $6,534 · 2025: $5,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,100 · Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,414.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,100.00 |
| Food and Beverage | $328.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12,628.88 | 2019-2023 | |
| Genentech USA, INC. | $10,865.25 | 2023-2025 | Polivy, Lunsumio, Columvi |
| E.R. Squibb & Sons, L.L.C. | $5,764.50 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $3,635.13 | 2019-2024 | Calquence |
| Abbvie INC. | $27.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.89 | 2025 | Iclusig |
| Sobi, INC | $19.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.